258 related articles for article (PubMed ID: 8495620)
21. Effect of hyperglycemia and the aldose reductase inhibitor tolrestat on sural nerve biochemistry and morphometry in advanced diabetic peripheral polyneuropathy. The Tolrestat Study Group.
Sima AA; Greene DA; Brown MB; Hohman TC; Hicks D; Graepel GJ; Bochenek WJ; Beg M; Gonen B
J Diabetes Complications; 1993; 7(3):157-69. PubMed ID: 8343610
[TBL] [Abstract][Full Text] [Related]
22. Withdrawal of the aldose reductase inhibitor tolrestat in patients with diabetic neuropathy: effect on nerve function. The Tolrestat Study Group.
Santiago JV; Snksen PH; Boulton AJ; Macleod A; Beg M; Bochenek W; Graepel GJ; Gonen B
J Diabetes Complications; 1993; 7(3):170-8. PubMed ID: 8343611
[TBL] [Abstract][Full Text] [Related]
23. Short-term effect of angiotensin-converting enzyme inhibitor enalapril in incipient diabetic nephropathy.
Abu-Romeh SH; Nawaz MK; Ali JH; Al-Suhaili AR; Abu-Jayyab AK
Clin Nephrol; 1989 Jan; 31(1):18-21. PubMed ID: 2536602
[TBL] [Abstract][Full Text] [Related]
24. Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy.
Hommel E; Andersen P; Gall MA; Nielsen F; Jensen B; Rossing P; Dyerberg J; Parving HH
Diabetologia; 1992 May; 35(5):447-51. PubMed ID: 1521727
[TBL] [Abstract][Full Text] [Related]
25. Vitamin D analogue therapy, cardiovascular risk and kidney function in people with Type 1 diabetes mellitus and diabetic nephropathy: a randomized trial.
Joergensen C; Tarnow L; Goetze JP; Rossing P
Diabet Med; 2015 Mar; 32(3):374-81. PubMed ID: 25307511
[TBL] [Abstract][Full Text] [Related]
26. Reduction of protein intake decreases glomerular filtration rate in young type 1 (insulin-dependent) diabetic patients mainly in hyperfiltering patients.
Rudberg S; Dahlquist G; Aperia A; Persson B
Diabetologia; 1988 Dec; 31(12):878-83. PubMed ID: 3240842
[TBL] [Abstract][Full Text] [Related]
27. [Microalbuminuria and tubular reabsorption of minerals in children with type 1 diabetes mellitus].
Sufliarska A; Michalková D; Tomecková E; Sílesová J; Lenková N; Kovács L
Bratisl Lek Listy; 1998 Jan; 99(1):26-32. PubMed ID: 9588076
[TBL] [Abstract][Full Text] [Related]
28. Effects of indomethacin on kidney function in type 1 (insulin-dependent) diabetic patients with nephropathy.
Hommel E; Mathiesen E; Arnold-Larsen S; Edsberg B; Olsen UB; Parving HH
Diabetologia; 1987 Feb; 30(2):78-81. PubMed ID: 3471610
[TBL] [Abstract][Full Text] [Related]
29. Effects of short-term strict metabolic control on kidney function and extracellular fluid volume in incipient diabetic nephropathy.
Mathiesen ER; Gall MA; Hommel E; Skøtt P; Parving HH
Diabet Med; 1989; 6(7):595-600. PubMed ID: 2527700
[TBL] [Abstract][Full Text] [Related]
30. The effect of an aldose reductase inhibitor (Epalrestat) on diabetic nephropathy in rats.
Itagaki I; Shimizu K; Kamanaka Y; Ebata K; Kikkawa R; Haneda M; Shigeta Y
Diabetes Res Clin Pract; 1994 Oct; 25(3):147-54. PubMed ID: 7851268
[TBL] [Abstract][Full Text] [Related]
31. Renal functional reserve in IDDM patients.
Sackmann H; Tran-Van T; Tack I; Hanaire-Broutin H; Tauber JP; Ader JL
Diabetologia; 1998 Jan; 41(1):86-93. PubMed ID: 9498635
[TBL] [Abstract][Full Text] [Related]
32. Diabetic nephropathy and arterial hypertension. The effect of antihypertensive treatment.
Parving HH; Andersen AR; Smidt UM; Christiansen JS; Oxenbøll B; Svendsen PA
Diabetes; 1983 May; 32 Suppl 2():83-7. PubMed ID: 6400672
[TBL] [Abstract][Full Text] [Related]
33. Glomerular dysfunction in diabetic nephropathy.
Zucchelli P; Zuccalà A; Sturani A
Postgrad Med J; 1988; 64 Suppl 3():22-30; discussion 48-9. PubMed ID: 3074295
[TBL] [Abstract][Full Text] [Related]
34. Protection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy.
Parving HH; Hommel E; Smidt UM
BMJ; 1988 Oct; 297(6656):1086-91. PubMed ID: 3143437
[TBL] [Abstract][Full Text] [Related]
35. Stable glomerular filtration rate in normotensive IDDM patients with stable microalbuminuria. A 5-year prospective study.
Mathiesen ER; Feldt-Rasmussen B; Hommel E; Deckert T; Parving HH
Diabetes Care; 1997 Mar; 20(3):286-9. PubMed ID: 9051373
[TBL] [Abstract][Full Text] [Related]
36. Galactose feeding causes glomerular hyperperfusion: prevention by aldose reductase inhibition.
Bank N; Coco M; Aynedjian HS
Am J Physiol; 1989 Jun; 256(6 Pt 2):F994-9. PubMed ID: 2500030
[TBL] [Abstract][Full Text] [Related]
37. A strong correlation between glomerular filtration rate and filtration surface in diabetic nephropathy.
Osterby R; Parving HH; Nyberg G; Hommel E; Jørgensen HE; Løkkegaard H; Svalander C
Diabetologia; 1988 May; 31(5):265-70. PubMed ID: 3396784
[TBL] [Abstract][Full Text] [Related]
38. Effect of tolrestat, an aldose reductase inhibitor, on neutrophil respiratory burst activity in diabetic patients.
Ihm SH; Yoo HJ; Park SW; Park CJ
Metabolism; 1997 Jun; 46(6):634-8. PubMed ID: 9186297
[TBL] [Abstract][Full Text] [Related]
39. Aldose reductase inhibition and glomerular abnormalities in diabetic rats.
Daniels BS; Hostetter TH
Diabetes; 1989 Aug; 38(8):981-6. PubMed ID: 2502460
[TBL] [Abstract][Full Text] [Related]
40. Effect of strict glycemic control on renal hemodynamic response to amino acids and renal enlargement in insulin-dependent diabetes mellitus.
Tuttle KR; Bruton JL; Perusek MC; Lancaster JL; Kopp DT; DeFronzo RA
N Engl J Med; 1991 Jun; 324(23):1626-32. PubMed ID: 2030719
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
